Sanofi India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 29, 2025, 4:14 pm

Market Cap	14,260 Cr.
Current Price	6,192
High / Low	7,600/4,146
Stock P/E	37.5
Book Value	374
Dividend Yield	1.89 %
ROCE	49.2 %
ROE	47.2 %
Face Value	10.0
PEG Ratio	-2.35

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Sanofi India Ltd

Competitors of Sanofi India Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	38.7 Cr.	52.2	94.9/45.2		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	36.3 Cr.	24.8	29.1/13.1	35.6	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	19,093.91 Cr	1,197.99		103.51	194.43	0.30%	16.64%	15.18%	6.18

All Competitor Stocks of Sanofi India Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	707	699	692	672	736	515	491	469	511	464	524	515	536
Expenses	512	538	510	505	507	393	377	370	374	348	404	397	364
Operating Profit	194	161	182	167	230	122	114	100	137	116	120	118	172
OPM %	28%	23%	26%	25%	31%	24%	23%	21%	27%	25%	23%	23%	32%
Other Income	142	16	11	34	44	57	82	77	41	21	2	14	3
Interest	0	0	0	0	0	1	0	0	0	0	0	0	0
Depreciation	11	11	10	10	10	9	9	9	9	9	9	10	10
Profit before tax	326	166	182	190	264	169	186	167	169	127	113	122	165
Tax %	27%	27%	28%	31%	28%	27%	18%	18%	19%	19%	27%	25%	28%
Net Profit	238	120	131	131	190	123	152	138	137	103	82	91	120
EPS in Rs	103.65	52.35	56.91	56.91	82.78	53.43	66.17	59.87	59.39	44.96	35.74	39.70	51.96

Last Updated: May 31, 2025, 7:53 am

Below is a detailed analysis of the quarterly data for Sanofi India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 536.00 Cr.. The value appears strong and on an upward trend. It has increased from 515.00 Cr. (Dec 2024) to 536.00 Cr., marking an increase of 21.00 Cr..
For Expenses, as of Mar 2025, the value is 364.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 397.00 Cr. (Dec 2024) to 364.00 Cr., marking a decrease of 33.00 Cr..
For Operating Profit, as of Mar 2025, the value is 172.00 Cr.. The value appears strong and on an upward trend. It has increased from 118.00 Cr. (Dec 2024) to 172.00 Cr., marking an increase of 54.00 Cr..
For OPM %, as of Mar 2025, the value is 32.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Dec 2024) to 32.00%, marking an increase of 9.00%.
For Other Income, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Dec 2024) to 3.00 Cr., marking a decrease of 11.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 10.00 Cr..
For Profit before tax, as of Mar 2025, the value is 165.00 Cr.. The value appears strong and on an upward trend. It has increased from 122.00 Cr. (Dec 2024) to 165.00 Cr., marking an increase of 43.00 Cr..
For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Dec 2024) to 28.00%, marking an increase of 3.00%.
For Net Profit, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Dec 2024) to 120.00 Cr., marking an increase of 29.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 51.96. The value appears strong and on an upward trend. It has increased from 39.70 (Dec 2024) to 51.96, marking an increase of 12.26.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 5:22 am

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	TTM
Sales	1,809	1,977	2,193	2,367	2,460	2,771	3,071	2,902	2,957	2,770	1,996	2,013	2,038
Expenses	1,411	1,639	1,817	1,832	1,921	2,146	2,403	2,186	2,194	2,066	1,508	1,522	1,513
Operating Profit	398	339	376	535	538	625	667	716	762	704	488	491	526
OPM %	22%	17%	17%	23%	22%	23%	22%	25%	26%	25%	24%	24%	26%
Other Income	83	131	218	66	79	88	33	45	564	204	318	79	40
Interest	0	0	0	2	1	1	0	2	2	2	2	2	2
Depreciation	92	97	113	119	102	103	100	82	67	42	36	37	37
Profit before tax	388	373	481	480	515	610	600	677	1,258	864	767	531	527
Tax %	32%	29%	33%	37%	37%	38%	31%	29%	25%	28%	21%	22%
Net Profit	265	264	322	304	326	381	414	478	944	621	603	414	396
EPS in Rs	115.30	114.61	139.78	132.26	141.74	165.48	180.09	207.65	410.61	269.83	262.26	179.78	172.36
Dividend Payout %	39%	39%	46%	51%	50%	51%	194%	176%	119%	211%	64%	65%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year
YoY Net Profit Growth (%)
Change in YoY Net Profit Growth (%)

No data available for trend analysis.

Growth

Compounded Sales Growth
10 Years:	0%
5 Years:	-8%
3 Years:	-12%
TTM:	3%

Compounded Profit Growth
10 Years:	8%
5 Years:	0%
3 Years:	-9%
TTM:	12%

Stock Price CAGR
10 Years:	11%
5 Years:	5%
3 Years:	15%
1 Year:	-8%

Return on Equity
10 Years:	24%
5 Years:	32%
3 Years:	41%
Last Year:	47%

Last Updated: Unknown

Balance Sheet

Last Updated: April 13, 2025, 2:52 pm

Month	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Equity Capital	23	23	23	23	23	23	23	23	23	23	23	23
Reserves	1,324	1,463	1,604	1,860	2,003	2,196	2,419	2,096	2,203	1,253	992	838
Borrowings	0	0	0	0	0	0	0	23	25	24	19	19
Other Liabilities	532	742	778	658	751	765	802	777	811	772	681	732
Total Liabilities	1,878	2,228	2,405	2,541	2,778	2,984	3,244	2,918	3,061	2,072	1,715	1,612
Fixed Assets	699	648	877	817	769	733	499	464	334	306	315	312
CWIP	136	210	22	34	30	21	17	10	13	24	16	18
Investments	0	0	0	0	0	0	0	0	0	0	2	0
Other Assets	1,043	1,369	1,505	1,690	1,978	2,230	2,728	2,444	2,714	1,743	1,382	1,281
Total Assets	1,878	2,228	2,405	2,541	2,778	2,984	3,244	2,918	3,061	2,072	1,715	1,612

Below is a detailed analysis of the balance sheet data for Sanofi India Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Equity Capital, as of Dec 2024, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 23.00 Cr..
For Reserves, as of Dec 2024, the value is 838.00 Cr.. The value appears to be declining and may need further review. It has decreased from 992.00 Cr. (Dec 2023) to 838.00 Cr., marking a decrease of 154.00 Cr..
For Borrowings, as of Dec 2024, the value is 19.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Dec 2023) which recorded 19.00 Cr..
For Other Liabilities, as of Dec 2024, the value is 732.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 681.00 Cr. (Dec 2023) to 732.00 Cr., marking an increase of 51.00 Cr..
For Total Liabilities, as of Dec 2024, the value is 1,612.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,715.00 Cr. (Dec 2023) to 1,612.00 Cr., marking a decrease of 103.00 Cr..
For Fixed Assets, as of Dec 2024, the value is 312.00 Cr.. The value appears to be declining and may need further review. It has decreased from 315.00 Cr. (Dec 2023) to 312.00 Cr., marking a decrease of 3.00 Cr..
For CWIP, as of Dec 2024, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Dec 2023) to 18.00 Cr., marking an increase of 2.00 Cr..
For Investments, as of Dec 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Dec 2023) to 0.00 Cr., marking a decrease of 2.00 Cr..
For Other Assets, as of Dec 2024, the value is 1,281.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,382.00 Cr. (Dec 2023) to 1,281.00 Cr., marking a decrease of 101.00 Cr..
For Total Assets, as of Dec 2024, the value is 1,612.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,715.00 Cr. (Dec 2023) to 1,612.00 Cr., marking a decrease of 103.00 Cr..

Notably, the Reserves (838.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Cash from Operating Activity +	273	265	213	322	435	374	412	611	559	399	231	462
Cash from Investing Activity +	-335	61	36	-155	-79	-73	66	276	631	651	36	-178
Cash from Financing Activity +	-105	-122	-147	-180	-188	-197	-183	-810	-849	-1,583	-878	-392
Net Cash Flow	-168	205	102	-13	168	104	295	78	341	-533	-612	-109

Free Cash Flow

Month	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Free Cash Flow	398.00	339.00	376.00	535.00	538.00	625.00	667.00	693.00	737.00	680.00	469.00	472.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023
Debtor Days	23	24	21	24	22	29	21	27	19	18	17	17
Inventory Days	135	151	179	173	169	151	154	127	107	110	125	202
Days Payable	75	83	122	81	79	119	110	100	93	105	109	89
Cash Conversion Cycle	83	92	78	115	112	61	65	54	33	22	33	130
Working Capital Days	3	43	26	9	79	17	18	35	-7	-19	-18	25
ROCE %	23%	29%	22%	26%	27%	26%	29%	28%	32%	35%	41%	71%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%	60.40%
FIIs	9.22%	8.99%	8.71%	8.26%	6.99%	6.71%	6.72%	6.80%	6.31%	6.11%	5.81%	5.78%
DIIs	19.05%	18.65%	18.59%	18.28%	19.22%	19.46%	19.65%	21.68%	22.51%	22.88%	22.60%	22.62%
Public	11.33%	11.96%	12.30%	13.08%	13.41%	13.43%	13.22%	11.10%	10.78%	10.61%	11.21%	11.20%
No. of Shareholders	50,916	59,276	64,542	73,734	74,593	76,694	71,513	68,598	62,870	61,849	67,662	66,211

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Aditya Birla Sun Life Frontline Equity Fund	268,508	0.84	216.62	268,508	2025-04-22 17:25:21	0%
Nippon India Pharma Fund	236,008	2.94	190.4	236,008	2025-04-22 17:25:21	0%
Nippon India Growth Fund	226,766	0.78	182.94	226,766	2025-04-22 17:25:21	0%
Nippon India Small Cap Fund	196,342	0.36	158.4	196,342	2025-04-22 17:25:21	0%
SBI Contra Fund	161,000	0.68	129.5	161,000	2025-04-22 17:25:21	0%
Nippon India Multi Cap Fund	152,371	0.5	122.93	152,371	2025-04-22 17:25:21	0%
SBI Long Term Equity Fund	147,988	0.69	119.04	147,988	2025-04-22 17:25:21	0%
Aditya Birla Sun Life Small Cap Fund	144,433	2.22	116.52	144,433	2025-04-22 17:25:21	0%
SBI Magnum Midcap Fund	100,837	0.56	81.11	100,837	2025-04-22 17:25:21	0%
Aditya Birla Sun Life Multi-Cap Fund	87,342	1.43	70.46	87,342	2025-04-22 17:25:21	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Dec 24	Dec 23
FaceValue	10.00	10.00
Basic EPS (Rs.)	179.46	261.78
Diluted EPS (Rs.)	179.46	261.78
Cash EPS (Rs.)	195.65	279.35
Book Value[Excl.RevalReserv]/Share (Rs.)	374.17	441.39
Book Value[Incl.RevalReserv]/Share (Rs.)	374.17	441.39
Revenue From Operations / Share (Rs.)	875.30	1239.61
PBDIT / Share (Rs.)	220.57	377.83
PBIT / Share (Rs.)	204.61	360.61
PBT / Share (Rs.)	187.57	367.61
Net Profit / Share (Rs.)	179.69	262.13
NP After MI And SOA / Share (Rs.)	179.69	262.13
PBDIT Margin (%)	25.19	30.47
PBIT Margin (%)	23.37	29.09
PBT Margin (%)	21.42	29.65
Net Profit Margin (%)	20.52	21.14
NP After MI And SOA Margin (%)	20.52	21.14
Return on Networth / Equity (%)	48.02	59.38
Return on Capital Employeed (%)	52.72	77.98
Return On Assets (%)	25.64	35.15
Asset Turnover Ratio (%)	1.21	0.00
Current Ratio (X)	1.57	1.92
Quick Ratio (X)	0.87	0.89
Inventory Turnover Ratio (X)	0.60	0.00
Dividend Payout Ratio (NP) (%)	0.00	139.85
Dividend Payout Ratio (CP) (%)	0.00	131.23
Earning Retention Ratio (%)	0.00	-39.85
Cash Earning Retention Ratio (%)	0.00	-31.23
Interest Coverage Ratio (X)	338.20	511.18
Interest Coverage Ratio (Post Tax) (X)	235.27	345.18
Enterprise Value (Cr.)	13783.39	18147.83
EV / Net Operating Revenue (X)	6.85	6.37
EV / EBITDA (X)	27.17	20.88
MarketCap / Net Operating Revenue (X)	6.99	6.51
Retention Ratios (%)	0.00	-39.85
Price / BV (X)	16.36	18.28
Price / Net Operating Revenue (X)	6.99	6.51
EarningsYield	0.02	0.03

After reviewing the key financial ratios for Sanofi India Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Dec 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Dec 23) which recorded 10.00.
For Basic EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
For Diluted EPS (Rs.), as of Dec 24, the value is 179.46. This value is within the healthy range. It has decreased from 261.78 (Dec 23) to 179.46, marking a decrease of 82.32.
For Cash EPS (Rs.), as of Dec 24, the value is 195.65. This value is within the healthy range. It has decreased from 279.35 (Dec 23) to 195.65, marking a decrease of 83.70.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Dec 24, the value is 374.17. It has decreased from 441.39 (Dec 23) to 374.17, marking a decrease of 67.22.
For Revenue From Operations / Share (Rs.), as of Dec 24, the value is 875.30. It has decreased from 1,239.61 (Dec 23) to 875.30, marking a decrease of 364.31.
For PBDIT / Share (Rs.), as of Dec 24, the value is 220.57. This value is within the healthy range. It has decreased from 377.83 (Dec 23) to 220.57, marking a decrease of 157.26.
For PBIT / Share (Rs.), as of Dec 24, the value is 204.61. This value is within the healthy range. It has decreased from 360.61 (Dec 23) to 204.61, marking a decrease of 156.00.
For PBT / Share (Rs.), as of Dec 24, the value is 187.57. This value is within the healthy range. It has decreased from 367.61 (Dec 23) to 187.57, marking a decrease of 180.04.
For Net Profit / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
For NP After MI And SOA / Share (Rs.), as of Dec 24, the value is 179.69. This value is within the healthy range. It has decreased from 262.13 (Dec 23) to 179.69, marking a decrease of 82.44.
For PBDIT Margin (%), as of Dec 24, the value is 25.19. This value is within the healthy range. It has decreased from 30.47 (Dec 23) to 25.19, marking a decrease of 5.28.
For PBIT Margin (%), as of Dec 24, the value is 23.37. This value exceeds the healthy maximum of 20. It has decreased from 29.09 (Dec 23) to 23.37, marking a decrease of 5.72.
For PBT Margin (%), as of Dec 24, the value is 21.42. This value is within the healthy range. It has decreased from 29.65 (Dec 23) to 21.42, marking a decrease of 8.23.
For Net Profit Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 10. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
For NP After MI And SOA Margin (%), as of Dec 24, the value is 20.52. This value exceeds the healthy maximum of 20. It has decreased from 21.14 (Dec 23) to 20.52, marking a decrease of 0.62.
For Return on Networth / Equity (%), as of Dec 24, the value is 48.02. This value is within the healthy range. It has decreased from 59.38 (Dec 23) to 48.02, marking a decrease of 11.36.
For Return on Capital Employeed (%), as of Dec 24, the value is 52.72. This value is within the healthy range. It has decreased from 77.98 (Dec 23) to 52.72, marking a decrease of 25.26.
For Return On Assets (%), as of Dec 24, the value is 25.64. This value is within the healthy range. It has decreased from 35.15 (Dec 23) to 25.64, marking a decrease of 9.51.
For Asset Turnover Ratio (%), as of Dec 24, the value is 1.21. It has increased from 0.00 (Dec 23) to 1.21, marking an increase of 1.21.
For Current Ratio (X), as of Dec 24, the value is 1.57. This value is within the healthy range. It has decreased from 1.92 (Dec 23) to 1.57, marking a decrease of 0.35.
For Quick Ratio (X), as of Dec 24, the value is 0.87. This value is below the healthy minimum of 1. It has decreased from 0.89 (Dec 23) to 0.87, marking a decrease of 0.02.
For Inventory Turnover Ratio (X), as of Dec 24, the value is 0.60. This value is below the healthy minimum of 4. It has increased from 0.00 (Dec 23) to 0.60, marking an increase of 0.60.
For Dividend Payout Ratio (NP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 139.85 (Dec 23) to 0.00, marking a decrease of 139.85.
For Dividend Payout Ratio (CP) (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 131.23 (Dec 23) to 0.00, marking a decrease of 131.23.
For Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
For Cash Earning Retention Ratio (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 40. It has increased from -31.23 (Dec 23) to 0.00, marking an increase of 31.23.
For Interest Coverage Ratio (X), as of Dec 24, the value is 338.20. This value is within the healthy range. It has decreased from 511.18 (Dec 23) to 338.20, marking a decrease of 172.98.
For Interest Coverage Ratio (Post Tax) (X), as of Dec 24, the value is 235.27. This value is within the healthy range. It has decreased from 345.18 (Dec 23) to 235.27, marking a decrease of 109.91.
For Enterprise Value (Cr.), as of Dec 24, the value is 13,783.39. It has decreased from 18,147.83 (Dec 23) to 13,783.39, marking a decrease of 4,364.44.
For EV / Net Operating Revenue (X), as of Dec 24, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 6.37 (Dec 23) to 6.85, marking an increase of 0.48.
For EV / EBITDA (X), as of Dec 24, the value is 27.17. This value exceeds the healthy maximum of 15. It has increased from 20.88 (Dec 23) to 27.17, marking an increase of 6.29.
For MarketCap / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
For Retention Ratios (%), as of Dec 24, the value is 0.00. This value is below the healthy minimum of 30. It has increased from -39.85 (Dec 23) to 0.00, marking an increase of 39.85.
For Price / BV (X), as of Dec 24, the value is 16.36. This value exceeds the healthy maximum of 3. It has decreased from 18.28 (Dec 23) to 16.36, marking a decrease of 1.92.
For Price / Net Operating Revenue (X), as of Dec 24, the value is 6.99. This value exceeds the healthy maximum of 3. It has increased from 6.51 (Dec 23) to 6.99, marking an increase of 0.48.
For EarningsYield, as of Dec 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Dec 23) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Sanofi India Ltd as of July 4, 2025 is: 5,395.93

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of July 4, 2025, Sanofi India Ltd is Overvalued by 12.86% compared to the current share price 6,192.00

Intrinsic Value of Sanofi India Ltd as of July 4, 2025 is: 4,535.94

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of July 4, 2025, Sanofi India Ltd is Overvalued by 26.75% compared to the current share price 6,192.00

Last 5 Year EPS CAGR: -15.94%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 32.42%, which is a positive sign. The stock has a low average Working Capital Days of 17.58, which is a positive sign. The company has higher reserves (1,687.58 cr) compared to borrowings (9.17 cr), indicating strong financial stability. The company has shown consistent growth in sales (1.85 cr) and profit (524.15 cr) over the years.	The stock has a high average Cash Conversion Cycle of 73.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sanofi India Ltd:
1. Net Profit Margin: 20.52%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 52.72% (Industry Average ROCE: 16.64%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 48.02% (Industry Average ROE: 15.18%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 235.27
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.87
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 37.5 (Industry average Stock P/E: 103.51)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Sanofi India Ltd. is a Public Limited Listed company incorporated on 02/05/1956 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1956PLC009794 and registration number is 009794. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 2013.20 Cr. and Equity Capital is Rs. 23.00 Cr. for the Year ended 31/12/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Sanofi House, Mumbai Maharashtra 400072	igrc.sil@sanofi.com http://www.sanofiindialtd.com

Management
Name	Position Held
Mr. Aditya Narayan	Chairman & Ind.Director
Mr. Rodolfo Hrosz	Managing Director
Mr. Rachid Ayari	WholeTime Director & CFO
Ms. Renee Amonkar	Whole Time Director
Mr. Vaibhav Karandikar	Non Executive Director
Mrs. Usha Thorat	Independent Director
Mr. Rahul Bhatnagar	Independent Director

FAQ

What is the intrinsic value of Sanofi India Ltd?

Sanofi India Ltd's intrinsic value (as of 04 July 2025) is 5395.93 — 12.86% lower the current market price of 6,192.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 14,260 Cr. market cap, FY2025-2026 high/low of 7,600/4,146, reserves of 838 Cr, and liabilities of 1,612 Cr.

What is the Market Cap of Sanofi India Ltd?

The Market Cap of Sanofi India Ltd is 14,260 Cr..

What is the current Stock Price of Sanofi India Ltd as on 04 July 2025?

The current stock price of Sanofi India Ltd as on 04 July 2025 is 6,192.

What is the High / Low of Sanofi India Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Sanofi India Ltd stocks is ₹7,600/4,146.

What is the Stock P/E of Sanofi India Ltd?

The Stock P/E of Sanofi India Ltd is 37.5.

What is the Book Value of Sanofi India Ltd?

The Book Value of Sanofi India Ltd is 374.

What is the Dividend Yield of Sanofi India Ltd?

The Dividend Yield of Sanofi India Ltd is 1.89 %.

What is the ROCE of Sanofi India Ltd?

The ROCE of Sanofi India Ltd is 49.2 %.

What is the ROE of Sanofi India Ltd?

The ROE of Sanofi India Ltd is 47.2 %.

What is the Face Value of Sanofi India Ltd?

The Face Value of Sanofi India Ltd is 10.0.